STING1 and small cell lung carcinoma: Likewise, the RNA polymerase II inhibitor lurbinectedin has been shown to trigger DNA damage and potentiate PD-L1 blockade by activating the STING-IFN signaling axis in SCLC models, providing further mechanistic support for DDR-ICB synergy (59).